Skip to main content
SpringerLink
Log in
Book cover

High-Risk IV Medications in Special Patient Populations pp 221–250Cite as

Antihypertensives and Prostanoids

  • Chapter
  • First Online:

  • 873 Accesses

Abstract

Acute hypertension managed with intravenous antihypertensives has an all-cause in-hospital mortality rate of nearly 7%; with 59% of patients developing worsening organ dysfunction.1 The cost of hypertension associated with a secondary diagnosis in hospitalized patients is $2,734.2 Currently, national treatment guidelines for acute hypertension are not available for adult intensive care unit (ICU) patients. Recently, a survey was conducted to evaluate the management of acute hypertension.3 This survey discovered that only 8.2% of responders had a guideline in place to treat acute hypertension in non-stroke patients. There is also substantial variability in the intravenous agents selected to treat acute hypertension.1,3 In regards to the number of patients admitted to the ICU with acute hypertension, physicians surveyed reported that approximately five patients are admitted with a hypertensive emergency to their ICU each month and approximately the same number develop a hypertensive emergency during their ICU stay.3 With the frequency of acute hypertension and the safety concerns associated with intravenous antihypertensive agents, a review of the medications commonly used in the ICU to treat acute hypertension in special populations was conducted.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Katz JN, Gore JM, Amin A, et al. on behalf of the STAT Investigators. Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: results from the Studying the Treatment of Acute hyper Tension Registry. Am Heart J. 2009;158:599-606.

    Google Scholar 

  2. Wang G, Zhang Z, Ayala C. Hospitalization costs associated with hypertension as a secondary diagnosis among insured patients aged 18–64 years. Am J Hypertens. 2010;23:275-281.

    PubMed  CAS  Google Scholar 

  3. Benson J, Gerlach A, Dasta J. National survey of acute hypertension management. Crit Care Shock. 2008;11:154-166.

    Google Scholar 

  4. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425-1436.

    PubMed  CAS  Google Scholar 

  5. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477-1482.

    PubMed  CAS  Google Scholar 

  6. Barst RJ, Rubin LJ, Long WA, McGoon MD, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334(5):296-302.

    PubMed  CAS  Google Scholar 

  7. Gokhman R, Smithburger PL, Seybert AL, Kane-Gill SL. Pharmacokinetic Rationale for Combination Therapy in Pulmonary Arterial Hypertension. J Cardiovasc Pharmacol 2010;56(6):686-695.

    Google Scholar 

  8. Gessler T, Seeger W, Schmehl T. Inhaled prostainaoids in the therapy of pulmonary hypertension. J Aerosol Med Pulm Drug Deliv. 2008;21(1):1-12.

    PubMed  CAS  Google Scholar 

  9. Flaherty JF, Wong B, LaFollette G, Warnock DG, Julse JD, Gambertoglio JG. Pharmacokinetics of esmolol and ASL-8123 in renal failure. Clin Pharmacol Ther. 1989;45:321-327.

    PubMed  CAS  Google Scholar 

  10. Turlapaty P, Laddu A, Murthy VS, Singh B, Lee R. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings. Am Heart J. 1987;114:866-885.

    PubMed  CAS  Google Scholar 

  11. Lowenthal DT, Porter S, Saris SD, et al. Clinical pharmacology, pharmacodynamics and interactions with esmolol. Am J Cardiol. 1985;56:14F-18F.

    PubMed  CAS  Google Scholar 

  12. Buchi KN, Rollins DE, Tolman KG, et al. Pharmacokinetics of esmolol in hepatic disease. J Clin Pharmacol. 1987;27:880-884.

    PubMed  CAS  Google Scholar 

  13. Esmolol hydrochloride injection (package insert). Bedford, OH: Bedford Laboratories, Inc.; August 2008.

    Google Scholar 

  14. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2005;112(12):e154-e235.

    PubMed  Google Scholar 

  15. Felix SB, Stangl V, Kieback A, et al. Acute hemodynamic effects of beta-blockers in patients with severe congestive heart failure: comparison of celiprolol and esmolol. J Cardiovasc Pharmacol. 2001;38:666-671.

    Google Scholar 

  16. Barbier GH, Shettigar UR, Appunn DO. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol. Int J Clin Pharmacol Ther. 1995;33:212-218.

    PubMed  CAS  Google Scholar 

  17. Anonymous. Intravenous esmolol for the treatment of supraventricular tachyarrhytmia: results of a multicenter, baseline-controlled safety and efficacy study in 160 patients. Am Heart J. 1986;112:498-505.

    Google Scholar 

  18. Askenazi J, MacCosbe PE, Hoff J, Turlapaty P, Hua TA, Laddu A. Hemodynamic effects of esmolol, an ultra-short acting beta blocker. J Clin Pharmacol. 1987;27:567-573.

    PubMed  CAS  Google Scholar 

  19. Angaran DM, Schultz NJ, Tschida VH. Esmolol hydrochloride: an ultrashort-acting, β-adrenergic blocking agent. Clin Pharm. 1986;5:288-303.

    PubMed  CAS  Google Scholar 

  20. Lowenthal DT, Porter RS, Schari R, Turapaty P, Laddu AR, Matier WL. Esmolol-digoxin drug interaction. J Clin Pharmacol. 1987;27:561-566.

    PubMed  CAS  Google Scholar 

  21. Shettigar UR, Toole JG, Appunn DO. Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation and flutter. Am Heart J. 1993;126:368-374.

    PubMed  CAS  Google Scholar 

  22. Sagie A, Strasberg B, Kusnieck J, Sclarovsky S. Symptomatic bradycardia induced by the combination of oral diltiazem and beta blockers. Clin Cardiol. 1991;14:314-316.

    PubMed  CAS  Google Scholar 

  23. Leor J, Levartowsky D, Sharon C, Farfel Z. Amiodarone and B-adrenergic blockers: An interaction with metoprolol but not with atenolol. Am Heart J. 1988;116:206-207.

    PubMed  CAS  Google Scholar 

  24. Cheymol G, Poirier JM, Carrupt PA, Testa B, et al. Pharmacokinetics of β-adrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol. 1997;43:563-570.

    PubMed  CAS  Google Scholar 

  25. Walstad RA, Berg Kj, Wessel-Aas T, Nilsen OG. Labetalol in the treatment of hypertension in patients with normal and impaired renal function. Acta Med Scand Suppl. 1982;665:135-141.

    PubMed  CAS  Google Scholar 

  26. Wood AJ, Ferry DG, Bailey RR. Elimination kinetics of labetalol in severe renal failure. Br J Clin Pharmacol. 1982;13(suppl 1):81S-86S.

    PubMed  CAS  Google Scholar 

  27. Thompson FD, Joekes AM, Hussein MM. Monotherapy with labetalol for hypertensive patients with normal and impaired renal function. Br J Clin Pharmacol. 1979;8(suppl 2):129S-133s.

    PubMed  CAS  Google Scholar 

  28. MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3:193-219.

    PubMed  CAS  Google Scholar 

  29. Labetalol hydrochloride injection (package insert). Bedford, OH: Bedford Laboratories, Inc.; June 2000.

    Google Scholar 

  30. Halstenson Ce, Opsahl JA, Pence TV, et al. The disposition and dynamics of labetalol in patients on dialysis. Clin Pharmacol Ther. 1986;40:462-468.

    PubMed  CAS  Google Scholar 

  31. Homeida M, Jackson L, Roberts CJ. Decreased first-pass metabolism of labetalol in chronic liver disease. Br Med J. 1978;2:1048-1050.

    PubMed  CAS  Google Scholar 

  32. Wilson DJ, Wallin JD, Vlachakis ND, et al. Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. Am J Med. 1983;75:95-102.

    PubMed  CAS  Google Scholar 

  33. Rosei EA, Trust PM, Brown JJ. Intravenous labetalol in severe hypertension. Lancet. 1975;2:1093-1094.

    PubMed  CAS  Google Scholar 

  34. Marik PE, Varon J. Hypertensive crises challenges and management. Chest. 2007;131:1949-1962.

    PubMed  CAS  Google Scholar 

  35. Bailey RR. Labetalol in the treatment of patients with hypertension and renal function impairment. Br J Clin Pharmacol. 1979;8(suppl 2):135S-140S.

    PubMed  CAS  Google Scholar 

  36. Williams JG, DeVoos K, Craswell PW. Labetalol in the treatment of hypertensive renal patients. Med J Aust. 1978;25:225-228.

    Google Scholar 

  37. Clark JA, Zimmerman HJ, Tanner LA. Labetalol hepatotoxicity. Ann Intern Med. 1990;113:210-213.

    PubMed  CAS  Google Scholar 

  38. Douglas DD, Yang Rd, Jensen P, Thiele DL. Fatal labetalol-induced injury. Am J Med. 1989;87:235-236.

    PubMed  CAS  Google Scholar 

  39. Mason JM, Dickinson HO, Nicolson DJ, Campbell F, et al. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens. 2005;23:1777-1781.

    PubMed  CAS  Google Scholar 

  40. Kunz I, Schorr U, Klaus S, Sharma AM. Resting metabolic rate and substrate use in obesity hypertension. Hypertension. 2000;36:26-32.

    PubMed  CAS  Google Scholar 

  41. Lopressor (metoprolol tartrate). Suffern, NY: Novartis Pharmaceuticals Corporation; 2009.

    Google Scholar 

  42. Lloyd P, John VA, Signy M, Smith SE. The effect of impaired renal function on the pharmacokinetics of metoprolol after single administration of a 14/190 metoprolol OROS system. Am Heart J. 1990;20(2):478-482.

    Google Scholar 

  43. Seiler KU, Schuster KJ, Meyer GJ, et al. The pharmacokinetics of metoprolol and its metabolites in dialysis patients. Clin Pharmacokinet. 1980;5(2):192-198.

    PubMed  CAS  Google Scholar 

  44. Bennett WM, Aronoff GR, Morrison G, et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis. 1983;3:155-193.

    PubMed  CAS  Google Scholar 

  45. Bortolotti A, Castelli D, Verotta D, Bonati M. Pharmacokinetic and pharmacodynamic modeling of metoprolol in rabbits with liver failure. Eur J Drug Metab Pharmacokinet. 1989;14(2):145-151.

    PubMed  CAS  Google Scholar 

  46. Ross PJ, Lewis MJ, Sheridan DJ, et al. Adrenergic hypersensitivity after beta-blocker withdrawal. Br Heart J. 1981;45:637-642.

    PubMed  CAS  Google Scholar 

  47. Fishman WH. Bea-adrenergic blocker withdrawal. Am J Cardiol. 1987;59(13):26f-32f.

    Google Scholar 

  48. Walden RJ, Tomlinson B, Bhattacharjee P, Prichard BN. The beta-adrenergic blockade phenomenon. J Pharmacol. 1983;14(2):35-48.

    PubMed  Google Scholar 

  49. Cleviprex (package insert). Parsippany, NJ: The Medicines Company; 2008.

    Google Scholar 

  50. Phung OJ, Baker WL, White CM, Coleman CI. Focus on clevidipine. Formulary. 2009;44(4):102-107.

    CAS  Google Scholar 

  51. Deeks ED, Keating GM, Keam SJ. Clevidipine: a review of its use in the management of acute hypertension. Am J Cardiovasc Drugs. 2009;9(2):117-134.

    PubMed  CAS  Google Scholar 

  52. Vuylsteke A, Milner Q, Ericsson H, et al. Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashort-acting dihydropyridine, during cardiopulmonary bypass. Br J Anaesth. 2000;85(5):683-689.

    PubMed  CAS  Google Scholar 

  53. Ericsson H, Tholander B, Regardh CG. In vitro hydrolysis rate and protein-binding of clevidipine, a new ultrashort-acting calcium antagonist metabolized by esterases, in different animal species and man. Eur J Pharm Sci. 1999;8(1):29-37.

    PubMed  CAS  Google Scholar 

  54. Pollack CV, Varon J, Garrison NA, et al. Clevidipine, and intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med. 2009;53:329-338.

    PubMed  Google Scholar 

  55. Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008;107:1110-1121.

    PubMed  CAS  Google Scholar 

  56. Ericsson H, Bredburg U, Eriksson U, et al. Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers. Anesthesiology. 2000;92:993-1001.

    PubMed  CAS  Google Scholar 

  57. Levy JH, Mancoa MY, Gitter R, et al. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients” The results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth Analg. 2007;105:918-925.

    PubMed  CAS  Google Scholar 

  58. Erickson AL, DeGrado JR, Fanikos JR. Clevidipine: a short acting intravenous dihydropyridine calcium channel blocker for the management of hypertension. Pharmacotherapy. 2010;30(5):515-528.

    PubMed  CAS  Google Scholar 

  59. Dasta J, Boucher B, Brophy G, et al. Intravenous to oral conversion of antihypertensives: a toolkit for guideline development. Ann Pharmacother. 2010;44:1430-1447.

    PubMed  Google Scholar 

  60. Zhang JG, Dehal SS, Ho T, et al. Human Cytochrome P450 induction and inhibition potential of clevidipine and its primary metabolite H152/81. Drug Metab Dispos. 2006;34(5):734-737.

    PubMed  CAS  Google Scholar 

  61. Enalaprilat (package insert). Bedford, OH: Bedford Laboratories; June 2005.

    Google Scholar 

  62. Elung-Jensen T, Heisterberg J, Kamoer AL, et al. High serum enalaprilat in chronic renal failure. J Renin Angiotensin Aldosterone Syst. 2001;2(4):240-245.

    PubMed  CAS  Google Scholar 

  63. Greenbaum R, Zucchelli P, Caspi A, et al. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Br J Clin Pharmacol. 2001;49:23-31.

    Google Scholar 

  64. Kelly JG, Doyle GD, Carmody M, et al. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of hemodialysis. BrJ Clin Pharmacol. 1988;26:781-786.

    CAS  Google Scholar 

  65. Mirenda J, Edwards C. Prolonged hypotension by enalaprilat in a case of renal artery stenosis. Anesth Analg. 1992;75:1017-1020.

    PubMed  CAS  Google Scholar 

  66. Flack JM, Mensah GA, Ferrario CM. Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage. Curr Med Res Opin. 2000;16:66-79.

    PubMed  CAS  Google Scholar 

  67. Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin- converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357.

    PubMed  CAS  Google Scholar 

  68. Brown NJ, Ray WA, Snowden M, et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60:8-13.

    PubMed  CAS  Google Scholar 

  69. Elliott WJ. Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clin Pharmacol Ther. 1996;60:582-588.

    PubMed  CAS  Google Scholar 

  70. Schattner A, Kozak N, Friedman J. Captopril-induced jaundice: report of 2 cases and a review of 13 additional reports in the literature. Am J Med Sci. 2001;322(4):236-240.

    PubMed  CAS  Google Scholar 

  71. Chou JW, Yu CJ, Chuang PH, et al. Successful treatment of fosinopril-induced severe cholestatic jaundice with plasma exchange. Ann Pharmacother. 2008;42(12):1887-1892.

    PubMed  Google Scholar 

  72. Hydralazine hydrochloride injection (package insert). Shirley, NY: American Regent; January 2009.

    Google Scholar 

  73. Bennett WM, Aronoff GR, Golper TA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians; 1994.

    Google Scholar 

  74. Jackson G, Pierscianowski TA, Mahon W, et al. Inappropriate antihypertensive therapy in the elderly. Lancet. 1976;2:1317-1318.

    PubMed  CAS  Google Scholar 

  75. Finks SW, Finks AL, Self TH. Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure. South Med J. 2006;99(1):18-22.

    PubMed  Google Scholar 

  76. Vidrio H, Tena I. Hydralazine tachycardia and sympathetic cardiovascular reactivity in normal subjects. Clin Pharmacol Ther. 1980;28:587-591.

    PubMed  CAS  Google Scholar 

  77. Gould L, Reddy CVR, Zen B, et al. Electrophysiologic properties of hydralazine in man. Pace Clin Electrophysiol. 1980;3:548-554.

    CAS  Google Scholar 

  78. Haitas B, Meyer TE, Angel ME, Reef E. Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure. Br J Clin Pharmacol. 1990;29(3):366-368.

    PubMed  CAS  Google Scholar 

  79. Pezzarossa A, Cimicchi MC, Orlandi N, et al. Lack of effect of nicardipine and diltiazem on glucose- and arginine-induced insulin release in obese subjects. Cardiovasc Drugs Ther. 1988;2(5):669-672.

    PubMed  CAS  Google Scholar 

  80. Raccah D, Pettenuzzo-Mollo M, Provendier O, et al. Comparison of the effects of captopril and nicardipine on insulin sensitivity and thrombotic profile in patients with hypertension and android obesity CaptISM Study Group. Captopril Insulin Sensitivity Multicenter Study Group. Am J Hypertens. 1994;7(8):731-738.

    PubMed  CAS  Google Scholar 

  81. Cardene premixed intravenous injection (nicardipine hydrochloride premixed intravenous injection) package insert. Bedminster, NJ: EKR Therapeutics, Inc.; 2009.

    Google Scholar 

  82. Razak TA, McNeil JJ, Sewell BB, et al. The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine. Clin Pharmacol Ther. 1990;47(4):463-469.

    PubMed  CAS  Google Scholar 

  83. Reddy P, Yeh YC. Use of injectable nicardipine for neurovascular indications. Pharmacotherapy. 2009;29(4):398-409.

    PubMed  CAS  Google Scholar 

  84. Aya AGM, Mangin R, Hoffet M, et al. Intravenous nicardipine for severe hypertension in pre-eclampsia – effects of an acute treatment on mother and fetus. Intensive Care Med. 1999;25:1277-1281.

    PubMed  CAS  Google Scholar 

  85. Wang EQ, Fung HL. Effects of obesity on the pharmacodynamics of nitroglycerin in conscious rates. AAPS PharmSci. 2002;4(4):E28.

    PubMed  Google Scholar 

  86. Alpert JS. Nitrate therapy in the elderly. Am J Cardiol. 1990;65:23J-27J.

    PubMed  CAS  Google Scholar 

  87. Cahalan MK, Hashimoto Y, Aizawa K, et al. Elderly, conscious patients have an accentuated hypotensive response to nitroglycerin. Anesthesiology. 1992;77:646-655.

    PubMed  CAS  Google Scholar 

  88. Nitroglycerin injection (package insert). Shirley, NY: American Regent, Inc.; 2005.

    Google Scholar 

  89. Devlin J, Dasta JF, Kleinschmidt K, Varon J. Patterns of antihypertensive use in patients with acute severe hypertension from a non-neurological cause: The STAT Registry. Pharmacotherapy. 2010;30:1087-1096.

    PubMed  Google Scholar 

  90. Wainwright RJ, Foran JPM, Padaria SF, et al. The long-term safety and tolerability of trans­dermal glyceryl trinitrate, when used with a patch-free interval in patients with stable angina. Br J Clin Pharmacol. 1993;47:178-182.

    CAS  Google Scholar 

  91. Bank J. Migraine with aura after administration of sublingual nitroglycerin tablets. Headache. 2001;41:84-87.

    PubMed  CAS  Google Scholar 

  92. Olsson G, Allgen J. Is there an optimal prophylactic nitrate therapy? Eur Heart J. 1991;12(suppl A):21-23.

    PubMed  Google Scholar 

  93. GISSI-3 investigators. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343(8906):1115-1122.

    Google Scholar 

  94. Webb DJ, Freestone S, Allen MJ, et al. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol. 1999;83:21C-28C.

    PubMed  CAS  Google Scholar 

  95. Rindone JP, Sloane EP. Cyanide toxicity from sodium nitroprusside: risks and management. Ann Pharmacother. 1992;26:515-519.

    PubMed  CAS  Google Scholar 

  96. American Heart Association. Guidelines 2005 Cardiopulmonary resuscitation and emergency cardiovascular care. Part 7.4 Monitoring Medications. Circulation 2005;112;Iv-78-IV-83.

    Google Scholar 

  97. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for adults and Children. 5th ed. Philadelphia: American College of Physicians; 2007.

    Google Scholar 

  98. Nitropress (sodium nitroprusside) Injection Solution (package insert). Lake Forest, IL: Hospira, Inc.; October 2006.

    Google Scholar 

  99. Nessim SL, Richardson RM. Dialysis for thiocyanate intoxication: a case report and review of the literature. ASAIO J. 2006;52:749-781.

    Google Scholar 

  100. Lindquist P, Rosling H, Tydent H. Cyanide release from sodium nitroprusside drug in bypass in hypothermia. Acta Anaesthesiol Scand. 1989;33:686-688.

    Google Scholar 

  101. Moore RA, Geller EA, Gallagher JD, Clark DL. Effect of hypothermic cardiopulmonary bypass on nitroprusside metabolism. Clin Pharmacol Ther. 1995;37:680-683.

    Google Scholar 

  102. Varon J. Treatment of acute severe hypertension. Drugs. 2008;68:283-297.

    PubMed  CAS  Google Scholar 

  103. Mann T, Cohn PF, Holman LB, et al. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Results in 25 patients and comparison with nitroglycerin. Circulation. 1978;57:732-738.

    PubMed  CAS  Google Scholar 

  104. Pasch T, Schulz V, Hoppenshauser G. Nitroprusside-induced formation of cyanide and its detoxification with thiosulphate during deliberate hypotension. J Cardiovasc Pharmacol. 1983;5:77-85.

    PubMed  CAS  Google Scholar 

  105. Cohn JN, Franciosa JA, Francis GS, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med. 1982;306:1129-1135.

    PubMed  CAS  Google Scholar 

  106. Rhoney D, Peacock WF. Intravenous therapies for hypertensive emergencies, part 1. Am J Health Syst Pharm. 2009;66:1343-1352.

    PubMed  CAS  Google Scholar 

  107. Ivankovich AD, Braverman B, Stephens TS, Shulman M, Heyman HJ. Sodium thiosulfate disposition in humans: relation to sodium nitroprusside toxicity. Anesthesiology. 1983;58:11-17.

    PubMed  CAS  Google Scholar 

  108. Cheung AT, Cruz-Shiavone GE, Meng QC, et al. Cardiopulmonary bypass, hemolysis and nitroprusside induced cyanide toxicity. Anesth Analg. 2007;105:29-33.

    PubMed  CAS  Google Scholar 

  109. Flolan® (package insert). Research Triangle Park, NC: GlaxoSmithKline; January 2008.

    Google Scholar 

  110. Moncada S, Vane JR. Prostacyclin and blood coagulation. Drugs. 1981;21:430-437.

    PubMed  CAS  Google Scholar 

  111. Zussman RM, Rubin RH, Cato AE, et al. Hemodialysis using prostacyclin instead of heparin as the sole antithrombin agent. N Engl J Med. 1981;304:934-939.

    Google Scholar 

  112. Addonizio VP, Fisher CA, Bowen JC, et al. Prostacyclin in lieu of anticoagulation with heparin for extracorporeal circulation. Trans Am Soc Artif Intern Organs. 1981;27:304-307.

    PubMed  CAS  Google Scholar 

  113. Hory B, Saint-Miller Y, Perol JC. Prostacyclin as the sole antithrombic agent for acute renal failure hemodialysis. Nephron. 1983;73:669-678.

    Google Scholar 

  114. Fiaccadori E, Maggiore U, Rotelli C, et al. Continuous haemofiltration in acute renal failure with prostacyclin as the sole anti-haemostatic agent. Intensive Care Med. 2002;82:586-593.

    Google Scholar 

  115. Sulica R, Emre S, Poon M. Medical management of porto-pulmonary hypertension and right heart failure prior to living-related liver transplantation. Congest Heart Fail. 2004;10(4):192-194.

    PubMed  Google Scholar 

  116. Swanson KL, Wiesner RH, Nyberg SL, et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008;8(11):2445-2453.

    PubMed  CAS  Google Scholar 

  117. Jones K. Prostacyclin. In: Peacock AJ, ed. Pulmonary Circulation. A Handbook for Clinicians. London: Chapman & Hall; 1996:115-122.

    Google Scholar 

  118. Centers for Disease Control. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension–seven sites, United States, 2003–2006. MMWR Morb Mortal Wkly Rep. 2007;56(8):170-172.

    Google Scholar 

  119. Yap RL, Mermel LA. Micrococcus infection in patients receiving epoprostenol by continuous infusion. Eur J Clin Microbiol Infect Dis. 2003;22:704-705.

    PubMed  CAS  Google Scholar 

  120. Ventavis® (Iloprost inhalation solution) package insert. South San Francisco, CA: Actelion Pharmaceuticals US; April 2010.

    Google Scholar 

  121. Remodulin® (Treprostinil injection) package insert. Research Triangle Park, NC: United Therapeutics Corporation; January 2010.

    Google Scholar 

  122. Sakai T, Planinsic EM, Mathier MA, et al. Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease. Eur Soc Organ Transplant. 2009;22:554-561.

    CAS  Google Scholar 

  123. Wade MF, Baker FJ, Roscigno R, et al. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J Clin Pharmacol. 2004;44:83.

    PubMed  CAS  Google Scholar 

  124. Laliberte K, Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remoduln) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004;44(2):209-214.

    PubMed  CAS  Google Scholar 

  125. Skoro-Sajer N, Lang IM, Harja E, et al. A clinical comparison of slow-and rapid escalation treprostinil (Remodulin) dosing regimens in patients with pulmonary hypertension. Clin Pharmacokinet. 2008;47(9):611-618.

    Google Scholar 

  126. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an Epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41:293-299.

    PubMed  CAS  Google Scholar 

  127. Oudiz RJ, Farber HW. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an evidence-based review. Am Heart J. 2009;157:625-635.

    PubMed  CAS  Google Scholar 

  128. Tyvaso® (Treprostinil inhalation solution) package insert. Research Triangle Park, NC: United Therapeutics Corporation; July 2009.

    Google Scholar 

  129. Tyvaso® inhalation system: care and replacement of the system. http://www.tyvaso.com/care_of_the_system.aspx. Accessed June 14, 2010.

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA, USA

    Pamela L. Smithburger

Authors
  1. Pamela L. Smithburger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandra L. Kane-Gill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pamela L. Smithburger .

Editor information

Editors and Affiliations

  1. University of Pittsburgh, Lothrop Street 200, Pittsburgh, 15213, Pennsylvania, USA

    Sandra Kane-Gill

  2. The Ohio State University, Ohio, USA, Round Rock, 78634-0967, USA

    Joseph Dasta

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag London Limited

About this chapter

Cite this chapter

Smithburger, P.L., Kane-Gill, S.L. (2011). Antihypertensives and Prostanoids. In: Kane-Gill, S., Dasta, J. (eds) High-Risk IV Medications in Special Patient Populations. Springer, London. https://doi.org/10.1007/978-0-85729-606-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-606-1_8

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-605-4

  • Online ISBN: 978-0-85729-606-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation